Matthew B Kraft

US Patent:

20110269713, Nov 3, 2011

Filed:

Oct 14, 2010

Appl. No.:

12/937793

Inventors:

Gary E. Keck - Salt Lake City UT, US
Matthew B. Kraft - Salt Lake City UT, US
Anh P. Truong - Burlingame CA, US
Carina C. Sanchez - Somerville MA, US
Wei Li - Salt Lake City UT, US
Jonathan A. Covel - San Diego CA, US
Dennie Welch - Lake Bluff IL, US
Yam Poudel - Salt Lake City UT, US

Assignee:

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

International Classification:

A61K 31/695
C07D 309/22
A61P 37/00
A61K 31/351
A61P 35/00
A61P 25/28
C07F 7/08
C07D 323/00

US Classification:

514 63, 549214, 549427, 549417, 549267, 514451, 514450

Abstract:

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.

US Patent:

20220372057, Nov 24, 2022

Filed:

Apr 14, 2022

Appl. No.:

17/720704

Inventors:

- Foster City CA, US
Matthew Kraft - Belmont CA, US
Marshall D. Young - San Mateo CA, US

International Classification:

C07H 9/06

Abstract:

The present disclosure describes methods of preparing carbanucleosides.

US Patent:

20170239212, Aug 24, 2017

Filed:

Aug 10, 2015

Appl. No.:

15/503495

Inventors:

- Salt Lake City UT, US
Matthew B. KRAFT - Salt Lake City UT, US
Anh P. TRUONG - Burlingame CA, US
Carina C. SANCHEZ - Somerville MA, US
Wei LI - Salt Lake City UT, US
Jonathan A. COVEL - San Diego CA, US
Dennie WELCH - Lake Bluff IL, US
Yam POUDEL - Salt Lake City UT, US
Mark E. PETERSEN - Salt Lake City UT, US

International Classification:

A61K 31/365

Abstract:

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including the treatment or prevention of viral infection. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in a low number of steps and with a high degree of substitution and specificity.